Clinic of Small Animals, University of Veterinary Medicine and Pharmacy, Komenskeho 73, 041 81 Kosice, Slovakia
Bibliografia
Wilkie D. Topical corticosteroidal and non-steroidal ophthalmic antiinflammatory agents. Vet Focus 1989; 1: 105-107.
Kaswan RL, Salisbury MA. Current therapy of canine keratoconjunctivitis sicca and rationale for change in treating the causal factor with topical cyclosporine. Vet Focus 1989; 1: 98-104.
Leung TG, Thorne JE Emerging drugs for the treatment of uveitis. Expert Opin Emerg Drugs. 2013 Dec;18(4):513-21. doi: 10.1517/14728214.2013.861417
Berchicci L, Miserocchi E, Di Nicola M, La Spina C, Bandello F, Modorati G. Clinical features of patients with episcleritis and scleritis in an Italian tertiary care referral center. Eur J Ophthalmol. 2013 Nov 12:0. doi: 10.5301/ejo.5000394
Lin P, Suhler EB, Rosenbaum JT.: The Future of Uveitis Treatment. Ophthalmology. 2013 Oct 26. doi:pii: S0161-6420(13)00777-X. 10.1016/j.ophtha.2013.08.029
Schoenwald R. Ocular drug delivery: pharmacokinetic considerations. Clinical Pharmacocinetics 1990; 18 : 255 – 269
Sasaki H, Yamamura K, Nishida K et al Delivery of drugs to the eye by topical application. Progress in Retina and Eye Research1996; 15: 583 – 620
Kaiser T, Werner A, Ba¨umer W et al Tissue distribution of dexamethasone in canine ocular compartments following topical application of dexamethasone – 21 – isonicotiamid and oxytetracycline HCL. Veterinary Ophthalmology 2008; 11: 335 – 339
McGhee CN. Pharmacokinetics of ophthalmic corticosteroids. British Journal of Ophthalmology 1992; 76: 681 – 684
Holmberg BJ, Maggs DJ. The use of corticosteroids to treat ocular inflammation. Veterinary Clinics of North America: Small Animal Practice 2004; 34; 693 – 705